<DOC>
	<DOCNO>NCT02324426</DOCNO>
	<brief_summary>Excessive free radical formation depletion brain 's primary antioxidant , glutathione , establish component Parkinson 's disease ( PD ) pathophysiology . While rationale therapeutic use reduce glutathione ( GSH ) PD , even preliminary evidence suggest use GSH lead symptomatic improvement , obstacle surround currently employ delivery method hinder clinical utility therapy . Intranasal GSH , ( ) GSH , novel method glutathione augmentation . The aim study evaluate whether 200 mg ( ) GSH result measurable change brain glutathione concentration , measure magnetic resonance spectroscopy ( MRS ) 15 individual PD .</brief_summary>
	<brief_title>CNS Uptake Intranasal Glutathione</brief_title>
	<detailed_description>Objectives Primary Aim : To determine whether intranasal reduce glutathione , ( ) GSH , capable augment CNS glutathione level . Hypothesis : Mean MRS glutathione concentration rise baseline follow administration 1 cc 200 mg/ml ( ) GSH . Design Outcomes : This pilot study seek obtain baseline data regard feasibility MRS detect change CNS glutathione concentration follow administration 200 mg ( ) GSH . CNS glutathione level measure use magnetic resonance spectroscopy ( MRS ) , putamen region interest . Baseline brain GSH concentration measure MRS approximately time day individual administration study medication . Outcome Measure : Describe change mean GSH concentration follow administration ( ) GSH . The data analysis ipsative- result report percent change individual 's baseline GSH concentration . Interventions Duration : If participant communicates he/she understands study , meet inclusion criterion , provide informed consent , individual schedule single visit University Washington MR imaging ( MRI ) , clinical evaluation , blood draw . ( ~ 3 hour ) . Participants ask optimally medicate time study visit , best ability . Sample Size Population : This proof-of-concept pilot trial . Based data single test subject , sample size 15 would provide 80 % power detect increase CNS glutathione concentration pre- post- administration value , willing accept alpha value 0.2 . 1.1 Primary Aims Primary Aim : To determine whether intranasal reduce glutathione , ( ) GSH , capable augment CNS glutathione concentration . ( Region Interest : putamen ) Hypothesis : Mean MRS glutathione concentration rise baseline approximately 15 minute follow administration 200 mg/ml ( ) GSH 1 cc saline . 1.2 Secondary Objectives Hypothesis : Baseline CNS glutathione concentration RBC glutathione concentration correlate . 1 . To determine whether brain MRS [ glutathione ] red blood cell ( RBC ) glutathione level correlate . Outcome : A ROC curve drawn mean brain [ glutathione ] RBC total glutathione .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Age &gt; 18 year . Ability attend 3 hour study visit Seattle , WA . Ability read speak English . Have three require positive criterion PD Step 3 UK Brain Bank Diagnostic Criteria Parkinson 's Disease . A modify Hoehn &amp; Yahr Stage 23 . ( bilateral disease , severely disabled . ) Any contraindication magnetic resonance imaging , include pacemaker , pacemaker wire , aneurysm clip , electronic implant , weight 136 kg ( 300 lb ) , metal embed soft tissue eye , prosthetic eye , claustrophobia , substance abuse , use recreational drug , pregnancy , medical contraindication . A history epilepsy , stroke , brain surgery , structural brain disease . The presence serious illness ( discretion study clinician , e.g . concurrent cancer treatment . ) Pregnant . A history sulfur sensitivity , e.g . reaction Nacetylcysteine , MSM , SAMe . A recent history asthma . Supplementation glutathione ( oral , intravenous , intranasal , nebulized ) glutathione precursor , Nacetylcysteine , six month prior baseline study visit . History sensitivity sulfur contain medications/ supplement , i.e . NAC , MSM . Current drug alcohol use dependence . Inability/unwillingness provide informed consent . ( e.g . diagnosis dementia , confusion study goal participation . ) Acute infection ( e.g . upper respiratory , dermal ) previous 30 day . Diagnosis mental illness , ever . ( Mental illness associate glutathione depletion . ) Diagnosis chronic disease , ever . ( e.g . Hep C , autoimmune disease , etc . ) Head tremor head dyskinesia comfortably control 90 minute .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Reduced Glutathione</keyword>
	<keyword>CNS</keyword>
	<keyword>Glutathione</keyword>
	<keyword>Uptake</keyword>
	<keyword>Intranasal</keyword>
	<keyword>( ) GSH</keyword>
</DOC>